About Tempus
Industry:
HealthTech/Genomics
Founded:
2015
Founders:
Eric Lefkofsky
Status:
Public (NASDAQ: TEM)
Funding & Growth
Total Raised:
$1.3B+
Valuation:
$8B+
Stage:
Public
Key Investors:
NEA
Revolution Growth
Baillie Gifford
✓ Pros
- • Mission-driven (cancer focus)
- • Large clinical data assets
- • AI/ML focus
- • Rapid growth
- • Good equity potential
✗ Cons
- • Fast-paced, demanding
- • Chicago location (for some)
- • Startup growing pains
- • High expectations